SK287528B6 - Tekutá kompozícia vhodná na použitie v implantáte, jej použitie a tuhý implantát - Google Patents
Tekutá kompozícia vhodná na použitie v implantáte, jej použitie a tuhý implantát Download PDFInfo
- Publication number
- SK287528B6 SK287528B6 SK515-2003A SK5152003A SK287528B6 SK 287528 B6 SK287528 B6 SK 287528B6 SK 5152003 A SK5152003 A SK 5152003A SK 287528 B6 SK287528 B6 SK 287528B6
- Authority
- SK
- Slovakia
- Prior art keywords
- composition
- implant
- solid
- biodegradable
- polar aprotic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 146
- 239000007943 implant Substances 0.000 title claims abstract description 61
- 239000007787 solid Substances 0.000 title claims abstract description 38
- 230000009969 flowable effect Effects 0.000 title abstract description 17
- 108010000817 Leuprolide Proteins 0.000 claims abstract description 148
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims abstract description 108
- 229960004338 leuprorelin Drugs 0.000 claims abstract description 108
- 229920001169 thermoplastic Polymers 0.000 claims abstract description 50
- 239000003880 polar aprotic solvent Substances 0.000 claims abstract description 48
- 239000004416 thermosoftening plastic Substances 0.000 claims abstract description 46
- 229920000728 polyester Polymers 0.000 claims abstract description 45
- 210000001124 body fluid Anatomy 0.000 claims abstract description 20
- 239000010839 body fluid Substances 0.000 claims abstract description 20
- 239000012736 aqueous medium Substances 0.000 claims abstract description 16
- 238000013270 controlled release Methods 0.000 claims abstract description 16
- 239000011159 matrix material Substances 0.000 claims abstract description 11
- 238000011065 in-situ storage Methods 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims description 46
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 108700012941 GNRH1 Proteins 0.000 claims description 7
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 230000003628 erosive effect Effects 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 238000006065 biodegradation reaction Methods 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 239000001087 glyceryl triacetate Substances 0.000 claims description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 210000004761 scalp Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 18
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 72
- 229920000642 polymer Polymers 0.000 description 67
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 40
- 229940087857 lupron Drugs 0.000 description 40
- 229960003604 testosterone Drugs 0.000 description 36
- 210000002966 serum Anatomy 0.000 description 32
- 238000009472 formulation Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 24
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 23
- 241000282472 Canis lupus familiaris Species 0.000 description 23
- 239000000047 product Substances 0.000 description 14
- -1 in-situ formed Substances 0.000 description 12
- 239000004743 Polypropylene Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 229920001155 polypropylene Polymers 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 229920001577 copolymer Polymers 0.000 description 8
- 239000011859 microparticle Substances 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229920001897 terpolymer Polymers 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 229920006158 high molecular weight polymer Polymers 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
- B65D81/3205—Separate rigid or semi-rigid containers joined to each other at their external surfaces
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mechanical Engineering (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66617400A | 2000-09-21 | 2000-09-21 | |
| US09/711,758 US6565874B1 (en) | 1998-10-28 | 2000-11-13 | Polymeric delivery formulations of leuprolide with improved efficacy |
| PCT/US2001/029612 WO2002030393A2 (en) | 2000-09-21 | 2001-09-21 | Polymeric delivery formulations of leuprolide with improved efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK5152003A3 SK5152003A3 (en) | 2003-10-07 |
| SK287528B6 true SK287528B6 (sk) | 2011-01-04 |
Family
ID=27099398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK515-2003A SK287528B6 (sk) | 2000-09-21 | 2001-09-21 | Tekutá kompozícia vhodná na použitie v implantáte, jej použitie a tuhý implantát |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US6565874B1 (cs) |
| EP (3) | EP2158900B1 (cs) |
| JP (4) | JP2004510807A (cs) |
| KR (1) | KR100831113B1 (cs) |
| CN (2) | CN100536922C (cs) |
| AT (2) | ATE296088T3 (cs) |
| AU (4) | AU2001292931B2 (cs) |
| BR (1) | BRPI0114069B8 (cs) |
| CA (1) | CA2436275C (cs) |
| CY (3) | CY1106045T1 (cs) |
| CZ (1) | CZ303134B6 (cs) |
| DE (2) | DE60111068T3 (cs) |
| DK (3) | DK1586309T6 (cs) |
| ES (3) | ES2241876T7 (cs) |
| HU (1) | HU228386B1 (cs) |
| IL (2) | IL155006A0 (cs) |
| IS (1) | IS6794A (cs) |
| MX (1) | MXPA03002552A (cs) |
| NZ (1) | NZ525210A (cs) |
| PL (1) | PL226346B1 (cs) |
| PT (3) | PT2158900E (cs) |
| RU (1) | RU2271826C2 (cs) |
| SI (1) | SI1322286T1 (cs) |
| SK (1) | SK287528B6 (cs) |
| WO (1) | WO2002030393A2 (cs) |
| ZA (1) | ZA200302944B (cs) |
Families Citing this family (219)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US8226598B2 (en) * | 1999-09-24 | 2012-07-24 | Tolmar Therapeutics, Inc. | Coupling syringe system and methods for obtaining a mixed composition |
| DK1310517T4 (da) * | 2000-08-07 | 2011-01-17 | Wako Pure Chem Ind Ltd | Mælkesyrepolymer og fremgangsmåde til fremstilling af denne |
| US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
| AU2002324447B2 (en) | 2001-06-22 | 2006-06-29 | Durect Corporation | Zero-order prolonged release coaxial implants |
| TW200526267A (en) * | 2001-06-29 | 2005-08-16 | Takeda Chemical Industries Ltd | Controlled release composition and method of producing the same |
| ES2559927T3 (es) | 2002-06-07 | 2016-02-16 | Dyax Corp. | Prevención y reducción de pérdida de sangre y respuesta inflamatoria |
| CN1485072A (zh) * | 2002-09-28 | 2004-03-31 | 治疗前列腺疾病的薏苡仁油软胶囊及其应用 | |
| EP1622540A4 (en) * | 2003-03-11 | 2009-12-30 | Qlt Usa Inc | PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM |
| EA011169B1 (ru) * | 2003-03-14 | 2009-02-27 | Дебио Решерш Фармасётик С.А. | Система подкожной доставки, способ ее получения и ее применение для лечения холинергических дефицитных расстройств |
| CA2524286A1 (en) * | 2003-05-01 | 2004-11-18 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Li Mited | Nasal administration of the lh-rh analog leuprolide |
| US20040224000A1 (en) * | 2003-05-05 | 2004-11-11 | Romano Deghenghi | Implants for non-radioactive brachytherapy of hormonal-insensitive cancers |
| WO2004103342A2 (en) * | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
| DK1663281T3 (en) * | 2003-08-29 | 2014-03-17 | Dyax Corp | POLY-PEGYLED PROTEASE INHIBITORS |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| RU2006128593A (ru) * | 2004-01-07 | 2008-02-20 | Тримерис, Инк. (Us) | Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека |
| WO2005070444A2 (en) * | 2004-01-13 | 2005-08-04 | Vasogenix Pharmaceuticals, Inc. | Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same |
| EP1703916A2 (en) * | 2004-01-13 | 2006-09-27 | Vasogenix Pharmaceuticals, Inc. | Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same |
| CA2552677A1 (en) * | 2004-01-13 | 2005-07-28 | Vasogenix Pharmaceuticals, Inc. | Controlled release cgrp delivery composition for cardiovascular and renal indications |
| DE602005011928D1 (de) | 2004-01-20 | 2009-02-05 | Allergan Inc | Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure |
| BRPI0506793A (pt) * | 2004-02-20 | 2007-05-22 | Rinat Neuroscience Corp | métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 |
| WO2005084725A1 (en) * | 2004-03-02 | 2005-09-15 | Nanotherapeutics, Inc. | Compositions for repairing bone and methods for preparing and using such compositions |
| CN1942497B (zh) * | 2004-03-03 | 2012-02-01 | 宝利诺沃生物材料有限公司 | 用于二阶段或多阶段固化的生物相容性聚合物组合物 |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| CA2573668A1 (en) | 2004-07-12 | 2006-02-16 | Allergan, Inc. | Ophthalmic compositions and methods for treating ophthalmic conditions |
| ES2432556T3 (es) | 2004-08-04 | 2013-12-04 | Evonik Corporation | Métodos para fabricar dispositivos de suministro y sus dispositivos |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| AU2005294382A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| WO2006065951A2 (en) * | 2004-12-15 | 2006-06-22 | Qlt Usa, Inc. | Sustained delivery formulations of octreotide compounds |
| US20060189958A1 (en) * | 2005-02-21 | 2006-08-24 | Talton James D | Inverted cannula for use in reconstituting dry material in syringes |
| KR101072239B1 (ko) * | 2005-06-07 | 2011-10-12 | 생-고뱅 세라믹스 앤드 플라스틱스, 인코포레이티드 | 촉매 캐리어 |
| WO2007011340A1 (en) * | 2005-07-14 | 2007-01-25 | Voyager Pharmaceutical Corporation | Methods for treating prostate cancer |
| WO2007019578A2 (en) | 2005-08-08 | 2007-02-15 | Cytyc Corporation | Tumescent skin spacing method |
| GB0517673D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US8882747B2 (en) * | 2005-11-09 | 2014-11-11 | The Invention Science Fund I, Llc | Substance delivery system |
| US20080103746A1 (en) * | 2005-11-30 | 2008-05-01 | Searete Llc, A Limited Liability Corporation | Systems and methods for pathogen detection and response |
| US10296720B2 (en) * | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US7927787B2 (en) | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
| US7827042B2 (en) * | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
| US8340944B2 (en) | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
| US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
| US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
| US20070142287A1 (en) * | 2005-12-20 | 2007-06-21 | Biomed Solutions, Llc | Compositions And Methods For Treatment Of Cancer |
| WO2007082726A2 (de) * | 2006-01-17 | 2007-07-26 | Medigene Ag | Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen |
| AU2007207618B2 (en) | 2006-01-18 | 2011-03-24 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical compositions with enhanced stability |
| CA2637707A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corporation | Methods for treating obesity by administering a trkb antagonist |
| PT1989220E (pt) | 2006-02-02 | 2012-03-23 | Trimeris Inc | Péptidos inibidores de fusão de hiv com propriedades biológicas melhoradas |
| US20070248611A1 (en) * | 2006-02-02 | 2007-10-25 | Pfizer Inc | Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist |
| WO2007103346A2 (en) * | 2006-03-08 | 2007-09-13 | The University Of North Carolina At Chapel Hill | Polyester based degradable composition and implantable biomedical articles |
| KR101466933B1 (ko) * | 2006-07-11 | 2014-12-01 | 큐피에스 엘엘씨 | 펩타이드의 지속 방출 전달을 위한 의약 조성물 |
| US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| EP1917971A1 (en) * | 2006-10-27 | 2008-05-07 | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) | Substained release formulations comprising very low molecular weight polymers |
| US20080114076A1 (en) * | 2006-11-09 | 2008-05-15 | Alcon Manufacturing Ltd. | Punctal plug comprising a water-insoluble polymeric matrix |
| AR063620A1 (es) * | 2006-11-09 | 2009-02-04 | Alcon Res Ltd | Implante punctal que contiene una matriz polimerica insoluble en agua |
| JP5411703B2 (ja) * | 2006-11-09 | 2014-02-12 | アルコン リサーチ， リミテッド | 薬物送達のための水不溶性ポリマーマトリクス |
| NZ577281A (en) | 2006-12-18 | 2011-12-22 | Takeda Pharmaceutical | Sustained-release composition and method for producing the same |
| US7862598B2 (en) * | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US8642093B2 (en) * | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US20090110933A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices related to nitric oxide releasing materials |
| US7975699B2 (en) | 2007-10-30 | 2011-07-12 | The Invention Science Fund I, Llc | Condoms configured to facilitate release of nitric oxide |
| US8221690B2 (en) * | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
| ES2755374T3 (es) * | 2007-02-15 | 2020-04-22 | Tolmar Therapeutics Inc | Poli(lactida/glicolida) de descarga lenta y métodos para producir polímeros |
| CA2682848A1 (en) * | 2007-04-03 | 2008-10-16 | Trimeris, Inc. | Novel formulations for delivery of antiviral peptide therapeutics |
| MX354603B (es) | 2007-05-25 | 2018-03-13 | Indivior Uk Ltd | Formulaciones de transferencia sostenida de compuestos de risperidona. |
| RU2010113992A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение урокортина и кортиколиберина в качестве терапевтических средств |
| MX2010003179A (es) * | 2007-09-25 | 2010-04-30 | Trimeris Inc | Metodos de sintesis para peptidos anti-vih terapeuticos. |
| US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US7846400B2 (en) * | 2007-10-30 | 2010-12-07 | The Invention Science Fund I, Llc | Substrates for nitric oxide releasing devices |
| US7897399B2 (en) | 2007-10-30 | 2011-03-01 | The Invention Science Fund I, Llc | Nitric oxide sensors and systems |
| US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
| US20090112055A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
| US20090112193A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices that utilize photolyzable nitric oxide donors |
| US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| US8828354B2 (en) * | 2008-03-27 | 2014-09-09 | Warsaw Orthopedic, Inc. | Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin |
| US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
| US9125917B2 (en) * | 2008-04-18 | 2015-09-08 | Warsaw Orthopedic, Inc. | Fluocinolone formulations in a biodegradable polymer carrier |
| US9289409B2 (en) * | 2008-04-18 | 2016-03-22 | Warsaw Orthopedic, Inc. | Sulindac formulations in a biodegradable material |
| USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
| US8629172B2 (en) | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
| US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
| US20090263443A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedics, Inc. | Methods for treating post-operative effects such as spasticity and shivering with clondine |
| US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
| US9132085B2 (en) * | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
| US20090263451A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain |
| US9132119B2 (en) | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
| US9072727B2 (en) | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| US8420114B2 (en) * | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
| US20090264478A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Sulfasalazine formulations in a biodegradable polymer carrier |
| US8956641B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
| US8557273B2 (en) * | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
| US8722079B2 (en) * | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
| US20090264489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
| US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
| US8956636B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprosing ketorolac |
| WO2009148583A2 (en) * | 2008-06-03 | 2009-12-10 | Qlt Usa, Inc. | Method for improvement of octreotide bioavailability |
| US8877225B2 (en) * | 2008-06-03 | 2014-11-04 | Tolmar Therapeutics, Inc. | Controlled release copolymer formulation with improved release kinetics |
| US9486531B2 (en) * | 2008-06-03 | 2016-11-08 | Indivior Uk Limited | Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system |
| DK2291174T3 (en) * | 2008-06-03 | 2015-03-09 | Tolmar Therapeutics Inc | Liquid compositions comprising biocompatible oligomer-polymer compositions |
| US20100015049A1 (en) * | 2008-07-16 | 2010-01-21 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
| US9492375B2 (en) * | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
| CN101653422B (zh) * | 2008-08-20 | 2013-03-20 | 山东绿叶制药有限公司 | 利培酮缓释微球、其制备方法和用途 |
| US20100098746A1 (en) * | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
| US9161903B2 (en) | 2008-10-31 | 2015-10-20 | Warsaw Orthopedic, Inc. | Flowable composition that hardens on delivery to a target tissue site beneath the skin |
| US8822546B2 (en) * | 2008-12-01 | 2014-09-02 | Medtronic, Inc. | Flowable pharmaceutical depot |
| US8980317B2 (en) * | 2008-12-23 | 2015-03-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating infections comprising a local anesthetic |
| US8469779B1 (en) | 2009-01-02 | 2013-06-25 | Lifecell Corporation | Method for debristling animal skin |
| US20100226959A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Matrix that prolongs growth factor release |
| US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
| US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
| US8617583B2 (en) | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
| US8653029B2 (en) | 2009-07-30 | 2014-02-18 | Warsaw Orthopedic, Inc. | Flowable paste and putty bone void filler |
| US8231891B2 (en) | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
| US20110097375A1 (en) | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
| US20110097380A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Clonidine formulations having antimicrobial properties |
| US9504698B2 (en) * | 2009-10-29 | 2016-11-29 | Warsaw Orthopedic, Inc. | Flowable composition that sets to a substantially non-flowable state |
| US8597192B2 (en) | 2009-10-30 | 2013-12-03 | Warsaw Orthopedic, Inc. | Ultrasonic devices and methods to diagnose pain generators |
| US8758791B2 (en) * | 2010-01-26 | 2014-06-24 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
| US8475824B2 (en) * | 2010-01-26 | 2013-07-02 | Warsaw Orthopedic, Inc. | Resorbable matrix having elongated particles |
| US9125902B2 (en) * | 2010-01-28 | 2015-09-08 | Warsaw Orthopedic, Inc. | Methods for treating an intervertebral disc using local analgesics |
| US9486500B2 (en) | 2010-01-28 | 2016-11-08 | Warsaw Orthopedic, Inc. | Osteoimplant and methods for making |
| US9050274B2 (en) * | 2010-01-28 | 2015-06-09 | Warsaw Orthopedic, Inc. | Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| ES2390439B1 (es) * | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| SMT202100679T1 (it) | 2010-05-31 | 2022-01-10 | Laboratorios Farmaceuticos Rovi S A | Composizioni per impianti biodegradabili in-situ iniettabili |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| DK2394664T3 (en) | 2010-05-31 | 2016-09-12 | Laboratorios Farmacéuticos Rovi S A | Antipsychotic injectable depot composition |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| EP2585092A1 (en) | 2010-06-24 | 2013-05-01 | Torrent Pharmaceuticals Limited | Pharmaceutical composition containing goserelin for in-situ implant |
| US8246571B2 (en) | 2010-08-24 | 2012-08-21 | Warsaw Orthopedic, Inc. | Drug storage and delivery device having a retaining member |
| GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
| GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
| US8404268B2 (en) | 2010-10-26 | 2013-03-26 | Kyphon Sarl | Locally targeted anti-fibrotic agents and methods of use |
| US8740982B2 (en) | 2010-10-26 | 2014-06-03 | Kyphon Sarl | Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis |
| US9414930B2 (en) | 2010-10-26 | 2016-08-16 | Kyphon SÀRL | Activatable devices containing a chemonucleolysis agent |
| US9301946B2 (en) | 2010-12-03 | 2016-04-05 | Warsaw Orthopedic, Inc. | Clonidine and GABA compounds in a biodegradable polymer carrier |
| WO2012075447A2 (en) | 2010-12-03 | 2012-06-07 | Warsaw Orthopedic, Inc. | Compositions and methods for delivering clonidine and bupivacaine to a target tissue site |
| EP2658525B1 (en) | 2010-12-29 | 2017-08-30 | Medincell | Biodegradable drug delivery compositions |
| US9060978B2 (en) | 2011-01-24 | 2015-06-23 | Warsaw Orthopedic, Inc. | Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist |
| US9717779B2 (en) | 2011-01-31 | 2017-08-01 | Warsaw Orthopedic, Inc. | Implantable matrix having optimum ligand concentrations |
| US8637067B1 (en) | 2011-03-10 | 2014-01-28 | Lifecell Corporation | Elastic tissue matrix derived hydrogel |
| CA2832838C (en) | 2011-04-14 | 2019-08-13 | Lifecell Corporation | Regenerative tissue matrix flakes |
| US9592243B2 (en) | 2011-04-25 | 2017-03-14 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an anabolic agent for treatment of an injury |
| US9511077B2 (en) | 2011-04-25 | 2016-12-06 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an anabolic agent for wound healing |
| US9132194B2 (en) | 2011-07-12 | 2015-09-15 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an adhesive sheet containing a drug depot |
| US9205241B2 (en) | 2011-07-12 | 2015-12-08 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an adhesive material |
| US9089523B2 (en) | 2011-07-28 | 2015-07-28 | Lifecell Corporation | Natural tissue scaffolds as tissue fillers |
| KR101494594B1 (ko) | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| US9532863B2 (en) | 2011-12-20 | 2017-01-03 | Lifecell Corporation | Sheet tissue products |
| EP2793965B1 (en) | 2011-12-20 | 2019-02-20 | LifeCell Corporation | Flowable tissue products |
| EP3797801A1 (en) | 2012-01-24 | 2021-03-31 | LifeCell Corporation | Elongated tissue matrices |
| US9511018B2 (en) | 2012-04-05 | 2016-12-06 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable matrix |
| WO2013163186A1 (en) | 2012-04-24 | 2013-10-31 | Lifecell Corporation | Flowable tissue matrices |
| US8735504B2 (en) | 2012-05-02 | 2014-05-27 | Warsaw Orthopedic, Inc. | Methods for preparing polymers having low residual monomer content |
| BR112015000547B1 (pt) | 2012-07-13 | 2020-11-10 | Lifecell Corporation | método para tratar tecido |
| CA2885327A1 (en) | 2012-09-26 | 2014-04-03 | Lifecell Corporation | Processed adipose tissue |
| KR101586791B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
| WO2014123703A1 (en) | 2013-02-06 | 2014-08-14 | Lifecell Corporation | Methods for localized modification of tissue products |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| KR20230109785A (ko) | 2014-03-27 | 2023-07-20 | 다케다 파머수티컬 컴패니 리미티드 | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 |
| US9764122B2 (en) | 2014-07-25 | 2017-09-19 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having an occluding member |
| US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
| US20160106804A1 (en) * | 2014-10-15 | 2016-04-21 | Yuhua Li | Pharmaceutical composition with improved stability |
| NZ731309A (en) | 2014-11-07 | 2022-02-25 | Indivior Uk Ltd | Buprenorphine dosing regimens |
| KR102696721B1 (ko) * | 2015-08-03 | 2024-08-19 | 톨마 인터내셔날 리미티드 | 약물의 장기간 지속적인 투여를 위한 액체 폴리머 전달 시스템 |
| EP3377041B1 (en) | 2015-11-16 | 2023-10-25 | MedinCell S.A. | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| WO2017084973A1 (en) * | 2015-11-16 | 2017-05-26 | Evonik Röhm Gmbh | Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) |
| US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
| WO2017210109A1 (en) | 2016-06-03 | 2017-12-07 | Lifecell Corporation | Methods for localized modification of tissue products |
| USD802756S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
| US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
| US10497172B2 (en) * | 2016-12-01 | 2019-12-03 | Pinscreen, Inc. | Photorealistic facial texture inference using deep neural networks |
| WO2018118944A1 (en) | 2016-12-22 | 2018-06-28 | Lifecell Corporation | Devices and methods for tissue cryomilling |
| DK3576771T3 (da) | 2017-01-31 | 2022-05-30 | Veru Inc | Sammensætninger og fremgangsmåder til langvarig frigivelse af antagonister for gonadotropin-frigivende hormon (gnrh) |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| KR102412628B1 (ko) * | 2017-08-28 | 2022-06-23 | 차의과학대학교 산학협력단 | 전기분무 기술을 이용한 루프롤라이드 함유 서방성 미립구의 제조방법 |
| US10994018B2 (en) | 2017-09-27 | 2021-05-04 | Novel Pharma Inc. | Long-acting palmitic acid-conjugated GnRH derivative, and pharmaceutical composition containing same |
| US11123375B2 (en) | 2017-10-18 | 2021-09-21 | Lifecell Corporation | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products |
| EP3697460A1 (en) | 2017-10-18 | 2020-08-26 | LifeCell Corporation | Adipose tissue products and methods of production |
| JP7463273B2 (ja) | 2017-10-19 | 2024-04-08 | ライフセル コーポレーション | 流動性無細胞組織マトリックス製品および製造方法 |
| US11246994B2 (en) | 2017-10-19 | 2022-02-15 | Lifecell Corporation | Methods for introduction of flowable acellular tissue matrix products into a hand |
| GB2568526A (en) | 2017-11-20 | 2019-05-22 | Rebio Tech Oy | Composition |
| CN111511385B (zh) * | 2017-12-18 | 2024-05-03 | 逸达生物科技股份有限公司 | 具有选定的释放持续时间的药物组合物 |
| CA3087410A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| MX2020012458A (es) | 2018-05-24 | 2021-04-28 | Celanese Eva Performance Polymers Llc | Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular. |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| EP3856142A1 (en) * | 2018-09-25 | 2021-08-04 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
| CN109498852B (zh) * | 2018-12-29 | 2022-06-24 | 广州噢斯荣医药技术有限公司 | 治疗骨科疾病的生物降解材料及其应用 |
| US20200330547A1 (en) * | 2019-04-22 | 2020-10-22 | Tolmar International Limited | Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition |
| MX2021014540A (es) | 2019-05-27 | 2022-04-12 | Tolmar International Ltd | Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama. |
| CA3142151A1 (en) | 2019-05-30 | 2020-12-03 | Lifecell Corporation | Biologic breast implant |
| CN111214643A (zh) * | 2020-03-11 | 2020-06-02 | 苏州善湾生物医药科技有限公司 | 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用 |
| WO2022005169A1 (ko) | 2020-06-30 | 2022-01-06 | 주식회사 종근당 | Gnrh 유도체를 포함하는 주사용 조성물 |
| CA3197170A1 (en) | 2020-09-30 | 2022-04-07 | Tolmar International Limited | Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients |
| US11908233B2 (en) | 2020-11-02 | 2024-02-20 | Pinscreen, Inc. | Normalization of facial images using deep neural networks |
| SMT202400434T1 (it) | 2020-12-23 | 2025-01-14 | Tolmar International Ltd | Sistemi e metodi per gruppi valvole per siringhe di miscelazione |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| KR102386163B1 (ko) | 2021-12-03 | 2022-04-14 | (주)인벤티지랩 | 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법 |
| USD1029245S1 (en) | 2022-06-22 | 2024-05-28 | Tolmar International Limited | Syringe connector |
| WO2024117740A1 (ko) | 2022-11-28 | 2024-06-06 | 동국제약 주식회사 | 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법 |
| WO2025008759A1 (en) * | 2023-07-05 | 2025-01-09 | Tolmar International Limited | Polymeric leuprolide acetate formulations |
| WO2025124422A1 (zh) * | 2023-12-13 | 2025-06-19 | 长春金赛药业有限责任公司 | 一种原位皮下植入的女性激素调节组合物及其制备方法和应用 |
| WO2025196632A1 (en) | 2024-03-22 | 2025-09-25 | Tolmar International Limited | Systems and methods for mixing syringe valve assemblies and syringe formulations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3284417A (en) * | 1963-11-13 | 1966-11-08 | Union Carbide Corp | Process for the preparation of lactone polyesters |
| US3839297A (en) * | 1971-11-22 | 1974-10-01 | Ethicon Inc | Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures |
| US4040420A (en) * | 1976-04-22 | 1977-08-09 | General Dynamics | Packaging and dispensing kit |
| US4137921A (en) * | 1977-06-24 | 1979-02-06 | Ethicon, Inc. | Addition copolymers of lactide and glycolide and method of preparation |
| PH19942A (en) * | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| CH661206A5 (fr) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes. |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5487897A (en) * | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| US5198220A (en) | 1989-11-17 | 1993-03-30 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
| JP2988633B2 (ja) | 1990-03-16 | 1999-12-13 | 三和生薬株式会社 | 発毛・育毛剤 |
| AU2605592A (en) * | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| JP3277342B2 (ja) * | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| US5672659A (en) * | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| RU2084458C1 (ru) * | 1993-05-27 | 1997-07-20 | Институт высокомолекулярных соединений РАН | Декапептид, обладающий противоопухолевой активностью |
| DK1125577T3 (da) | 1994-04-08 | 2006-06-19 | Qlt Usa Inc | Væskeformige medikamentindföringspræparater |
| GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
| US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
| US5747637A (en) * | 1995-09-07 | 1998-05-05 | Mitsui Toatsu Chemicals, Inc. | Bioabsorbable polymer and process for preparing the same |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| CA2192782C (en) * | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| DK1238657T3 (da) * | 1996-02-02 | 2005-01-17 | Alza Corp | Vedvarende frigivelse af et aktivt middel ved anvendelse af et implanterbart system |
| CA2591581C (en) * | 1996-12-20 | 2013-01-29 | Alza Corporation | Gel composition and methods |
| JPH10279499A (ja) * | 1997-04-04 | 1998-10-20 | Takeda Chem Ind Ltd | 子宮粘膜適用製剤 |
| US5912225A (en) | 1997-04-14 | 1999-06-15 | Johns Hopkins Univ. School Of Medicine | Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same |
| US7128927B1 (en) * | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| KR100321854B1 (ko) * | 1998-12-30 | 2002-08-28 | 동국제약 주식회사 | 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법 |
| WO2001019887A1 (fr) | 1999-09-10 | 2001-03-22 | Mitsui Chemicals, Inc. | Resine de polyuretane biodegradable |
| US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
| US20070117959A1 (en) * | 2003-12-15 | 2007-05-24 | The Children's Hospital Of Philadelphia | Novel polyesters |
-
2000
- 2000-11-13 US US09/711,758 patent/US6565874B1/en not_active Expired - Lifetime
-
2001
- 2001-09-21 KR KR1020037004110A patent/KR100831113B1/ko not_active Expired - Lifetime
- 2001-09-21 ES ES01973341.9T patent/ES2241876T7/es active Active
- 2001-09-21 JP JP2002533836A patent/JP2004510807A/ja not_active Withdrawn
- 2001-09-21 EP EP09012462A patent/EP2158900B1/en not_active Revoked
- 2001-09-21 NZ NZ525210A patent/NZ525210A/en not_active IP Right Cessation
- 2001-09-21 SK SK515-2003A patent/SK287528B6/sk not_active IP Right Cessation
- 2001-09-21 PT PT90124629T patent/PT2158900E/pt unknown
- 2001-09-21 CN CNB018190014A patent/CN100536922C/zh not_active Expired - Lifetime
- 2001-09-21 PT PT05010806T patent/PT1586309E/pt unknown
- 2001-09-21 ES ES09012462T patent/ES2404559T3/es not_active Expired - Lifetime
- 2001-09-21 IL IL15500601A patent/IL155006A0/xx active IP Right Grant
- 2001-09-21 RU RU2003111180/15A patent/RU2271826C2/ru active
- 2001-09-21 WO PCT/US2001/029612 patent/WO2002030393A2/en not_active Ceased
- 2001-09-21 PT PT01973341T patent/PT1322286E/pt unknown
- 2001-09-21 DK DK05010806.7T patent/DK1586309T6/da active
- 2001-09-21 DK DK01973341.9T patent/DK1322286T6/da active
- 2001-09-21 DK DK09012462.9T patent/DK2158900T3/da active
- 2001-09-21 PL PL361671A patent/PL226346B1/pl unknown
- 2001-09-21 SI SI200130383T patent/SI1322286T1/xx unknown
- 2001-09-21 AT AT01973341T patent/ATE296088T3/de unknown
- 2001-09-21 ES ES05010806T patent/ES2341777T7/es active Active
- 2001-09-21 DE DE60111068.4T patent/DE60111068T3/de not_active Expired - Lifetime
- 2001-09-21 CN CN2009101646316A patent/CN101669900B/zh not_active Expired - Lifetime
- 2001-09-21 EP EP01973341.9A patent/EP1322286B3/en not_active Expired - Lifetime
- 2001-09-21 AU AU2001292931A patent/AU2001292931B2/en not_active Expired
- 2001-09-21 EP EP05010806.7A patent/EP1586309B3/en not_active Expired - Lifetime
- 2001-09-21 BR BRPI0114069A patent/BRPI0114069B8/pt not_active IP Right Cessation
- 2001-09-21 CA CA002436275A patent/CA2436275C/en not_active Expired - Fee Related
- 2001-09-21 AU AU9293101A patent/AU9293101A/xx active Pending
- 2001-09-21 HU HU0302981A patent/HU228386B1/hu active Protection Beyond IP Right Term
- 2001-09-21 AT AT05010806T patent/ATE458469T3/de unknown
- 2001-09-21 DE DE60141421T patent/DE60141421D1/de not_active Expired - Lifetime
- 2001-09-21 CZ CZ20031124A patent/CZ303134B6/cs not_active IP Right Cessation
- 2001-09-21 MX MXPA03002552A patent/MXPA03002552A/es active IP Right Grant
-
2003
- 2003-02-24 US US10/373,400 patent/US6773714B2/en not_active Expired - Lifetime
- 2003-03-19 IL IL155006A patent/IL155006A/en unknown
- 2003-04-15 ZA ZA200302944A patent/ZA200302944B/en unknown
- 2003-04-23 IS IS6794A patent/IS6794A/is unknown
-
2004
- 2004-06-21 US US10/872,671 patent/US20040229912A1/en not_active Abandoned
-
2005
- 2005-06-09 CY CY20051100707T patent/CY1106045T1/el unknown
-
2006
- 2006-11-24 AU AU2006241376A patent/AU2006241376B2/en not_active Expired
- 2006-12-21 US US11/643,505 patent/US20070104759A1/en not_active Abandoned
-
2010
- 2010-04-23 AU AU2010201645A patent/AU2010201645B2/en not_active Expired
- 2010-05-20 US US12/784,304 patent/US8486455B2/en not_active Expired - Fee Related
- 2010-05-20 US US12/784,343 patent/US9254307B2/en not_active Expired - Fee Related
- 2010-05-21 CY CY20101100453T patent/CY1110653T1/el unknown
-
2011
- 2011-10-14 JP JP2011227390A patent/JP5969190B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-19 CY CY20131100231T patent/CY1113920T1/el unknown
- 2013-09-11 JP JP2013187900A patent/JP6061823B2/ja not_active Expired - Lifetime
-
2014
- 2014-09-29 JP JP2014197886A patent/JP6087886B2/ja not_active Expired - Lifetime
-
2015
- 2015-02-11 US US14/619,621 patent/US20150150937A1/en not_active Abandoned
- 2015-11-02 US US14/930,387 patent/US20160106805A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK287528B6 (sk) | Tekutá kompozícia vhodná na použitie v implantáte, jej použitie a tuhý implantát | |
| AU2001292931A1 (en) | Polymeric delivery formulations of leuprolide with improved efficacy | |
| HK1141459B (en) | Polymeric delivery formulations of leuprolide with improved efficacy | |
| HK1139596B (en) | Polymeric delivery formulations of leuprolide with improved efficacy | |
| SI23170A (sl) | Polimerne dajalne formulacije levprolida z izboljšano učinkovitostjo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Assignment and transfer of rights |
Owner name: QLT USA, INC., FORT COLLINS, CO, US Free format text: FORMER OWNER: ATRIX LABORATORIES, INC., FORT COLLINS, CO, US Effective date: 20110119 |
|
| TC4A | Change of owner's name |
Owner name: TOLMAR THERAPEUTICS, INC., FORT COLLINS, CO, US Effective date: 20110119 |
|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20120921 |